Arctic Vision Reports the First Patient Enrollment in P-III Clinical Trial of ARVN003 for the Treatment of Presbyopia
Shots:
- The first patient has been enrolled in a P-III clinical study evaluating the efficacy & safety of ARVN003 in adults with presbyopia to temporary improve vision
- The results from the P-III (VISION-1) study showed that MicroLine 2% was statistically superior to PBO as determined by improvement in high contrast binocular distance corrected near visual acuity measured in low light conditions 2hrs. after treatment
- In Aug 2020, Arctic Vision obtained an exclusive license for the development and commercialization of ARVN003 (MicroLine) in Greater China & South Korea from Eyenovia. ARVN003 is a pilocarpine formulation that utilizes the microdosing platform Optejet for the treatment of presbyopia
Ref: PRNewswire | Image: Arctic Vision
Click here to read the full press release
Neha is a Senior Editor at PharmaShots. She is passionate and very enthusiastic about recent updates and developments in the life sciences and pharma industry. She covers Biopharma, MedTech, and Digital health segments along with different reports at PharmaShots. She can be contacted at connect@pharmashots.com.
